There has been much development in the area of tumour-stroma interactions dictating treatment resistance, with much recent interest in how hepatocyte growth factor (HGF) can mediate BRAF-inhibitor resistance in melanoma [43], [44]. The gene discussed is BRAF; the disease is melanoma.